Patents by Inventor Changlin Dou

Changlin Dou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250121082
    Abstract: An antibody or an antigen-binding fragment thereof that binds to CD228, and an antibody-drug conjugate containing the antibody or antigen-binding fragment thereof. The antibody or antigen-binding fragment thereof has a high affinity to a CD228 protein and an ability to mediate ADCC. The antibody-drug conjugate exhibits an inhibitory effect on various tumors. A nucleic acid encoding the antibody or antigen-binding fragment thereof; a cell containing the nucleic acid; a pharmaceutical composition containing the antibody or antigen-binding fragment thereof, the nucleic acid, the cell or the antibody-drug conjugate; and a kit. The use of the antibody or antigen-binding fragment thereof, the nucleic acid, the antibody-drug conjugate or the pharmaceutical composition in the prevention, treatment, detection or diagnosis of diseases related to CD228.
    Type: Application
    Filed: May 25, 2023
    Publication date: April 17, 2025
    Inventors: Deyong SONG, Jing HAN, Hong LIU, Nan SHEN, Jie JIAO, Qiaoping WANG, Jianxia FENG, Min LI, Mengqi ZONG, Ying LI, Changlin DOU
  • Publication number: 20240342283
    Abstract: An ROR1 CAR or ROR1/CD19 Dual CAR for the treatment of tumors. The T cells expressing ROR1 CAR or ROR1/CD19 Dual CAR can be stimulated by ROR1-positive or ROR1/CD19-positive cells, and have cytotoxicity against ROR1-positive or ROR1/CD19-positive cells.
    Type: Application
    Filed: August 15, 2022
    Publication date: October 17, 2024
    Inventors: Mengqi Zong, Jie Jiao, Jianxia Feng, Michael Harris, Xin Kai, Li Zhou, Ninghai Wang, Liangjun Wei, Hao Chen, Xian Wen, Changlin Dou, Chuangchuang Dong
  • Patent number: 10696973
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: June 30, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Changlin Dou, James P. Fandl
  • Publication number: 20180216118
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked, Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Application
    Filed: March 27, 2018
    Publication date: August 2, 2018
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Changlin Dou, James P. Fandl
  • Patent number: 9944934
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: April 17, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gang Chen, Changlin Dou, James P. Fandl
  • Patent number: 9469856
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: October 18, 2016
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Changlin Dou, Gang Chen, James P. Fandl
  • Publication number: 20160222094
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Application
    Filed: April 13, 2016
    Publication date: August 4, 2016
    Inventors: Gang Chen, Changlin Dou, James P. Fandl
  • Publication number: 20140315249
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Application
    Filed: February 18, 2014
    Publication date: October 23, 2014
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Changlin DOU, Gang CHEN, James P. FANDL
  • Patent number: 8673589
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: March 18, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Changlin Dou, James P. Fandl
  • Publication number: 20090162901
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells are provided. Expression of a nucleotide sequence of interest encoding a protein of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When a cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale bioreactor production of a desired protein of interest in eukaryotic cells.
    Type: Application
    Filed: November 25, 2008
    Publication date: June 25, 2009
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Gang Chen, Changlin Dou, James P. Fandl
  • Patent number: 7514545
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells. Expression of a nucleotide sequence of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a ligand-binding domain. When the cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale production of a desired product in eukaryotic cells.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: April 7, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: James P. Fandl, Changlin Dou
  • Patent number: 7455988
    Abstract: Compositions and methods for the inducible expression of genes in eukaryotic cells. Expression of a nucleotide sequence of interest is controlled by a regulatory fusion protein that consists of a transcription blocking domain and a legends-binding domain. When the cognate ligand for the ligand-binding domain is present, transcription of the nucleotide sequence of interest is blocked. Upon removal of the cognate ligand, the nucleotide sequence of interest is transcribed. The method is useful for large scale production of a desired product in eukaryotic cells.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: November 25, 2008
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: James P. Fandl, Changlin Dou